Dyslipidemia (Metabolic Disorder) – Drugs In Development, 2021

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Dyslipidemia – Drugs In Development, 2021, provides an overview of the Dyslipidemia (Metabolic Disorders) pipeline landscape.

Dyslipidemia is defined as elevation of the total cholesterol, the "bad" low-density lipoprotein (LDL) cholesterol and the triglyceride concentrations, and a decrease in the "good" high-density lipoprotein (HDL) cholesterol concentration in the blood. Numerous factors and causes can lead to an abnormality in the levels of lipids in the blood such as genetic predisposition, diet, age and gender, type II diabetes. Common symptoms that may be encountered in relation to dyslipidemia include corneal opacification, corneal arcus, xanthomas, balance impairment, pain in the calf when walking, dizziness and confusion.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Dyslipidemia – Drugs In Development, 2021, provides comprehensive information on the therapeutics under development for Dyslipidemia (Metabolic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Dyslipidemia (Metabolic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Dyslipidemia and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 9, 32, 23, 24, 3, 34, 14 and 3 respectively. Similarly, the Universities portfolio in Phase I, Preclinical and Discovery stages comprises 1, 14 and 4 molecules, respectively.

Dyslipidemia (Metabolic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

– The pipeline guide provides a snapshot of the global therapeutic landscape of Dyslipidemia (Metabolic Disorders).

– The pipeline guide reviews pipeline therapeutics for Dyslipidemia (Metabolic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.

– The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

– The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

– The pipeline guide reviews key companies involved in Dyslipidemia (Metabolic Disorders) therapeutics and enlists all their major and minor projects.

– The pipeline guide evaluates Dyslipidemia (Metabolic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

– The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

– The pipeline guide reviews latest news related to pipeline therapeutics for Dyslipidemia (Metabolic Disorders)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

- Find and recognize significant and varied types of therapeutics under development for Dyslipidemia (Metabolic Disorders).

- Classify potential new clients or partners in the target demographic.

- Develop tactical initiatives by understanding the focus areas of leading companies.

- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.

- Formulate corrective measures for pipeline projects by understanding Dyslipidemia (Metabolic Disorders) pipeline depth and focus of Indication therapeutics.

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Companies mentioned

89bio Inc

ABIONYX Pharma SA

AD Pharmaceuticals Co Ltd

Addpharma Inc

Affina Biotechnologies Inc

Afimmune Biopharma Ltd

Akcea Therapeutics Inc

Amarin Corp Plc

Arrakis Therapeutics Inc

Arrowhead Pharmaceuticals Inc

AstraZeneca Plc

AVVA Pharmaceuticals AG

Bio-Thera Solutions Ltd

BioRestorative Therapies Inc

Boryung Pharmaceutical Co Ltd

Cadila Healthcare Ltd

Cardax Inc

Celltrion Inc

Celon Pharma SA

Centaurus Therapeutics Inc

Centeer BioTherapeutics Ltd Co

Chong Kun Dang Holdings Corp

CMG Pharmaceutical Co Ltd

Corvidia Therapeutics Inc

CVI Pharmaceuticals US Inc

Daewon Pharmaceutical Co Ltd

Daewoong Pharmaceutical Co Ltd

Daiichi Sankyo Co Ltd

Delivra Corp

Dicerna Pharmaceuticals Inc

DongKoo Bio & Pharma Co Ltd

Eccogene (Shanghai) Co Ltd

Eli Lilly and Co

Elyson Pharmaceutical Co Ltd

Gilead Sciences Inc

Golden Biotechnology Corp

Guangzhou Jiayue Pharmaceutical Technology Co Ltd

Halo Therapeutics Ltd

Handok Inc

Hanlim Pharm Co Ltd

Hanmi Pharmaceuticals Co Ltd

HK inno.N Corp

Huons Co Ltd

Ildong Pharmaceutical Co Ltd

Inovio Pharmaceuticals Inc

Japan Tobacco Inc

Jeil Pharmaceutical Co Ltd

Jenrin Discovery Inc

Jiangsu Hengrui Medicine Co Ltd

JW Pharmaceutical Corp

Kolmar Pharma Co Ltd

Korea United Pharm Inc

Kotobuki Pharmaceutical Co Ltd

Kowa Co Ltd

Kuhnil Pharmaceutical Co Ltd

Kyorin Pharmaceutical Co Ltd

Kyung Dong Co Ltd

Les Laboratoires Servier SAS

Liid Pharmaceuticals Inc

LipimetiX Development Inc

Lyndra Therapeutics Inc.

Matinas BioPharma Holdings Inc

MD Healthcare Inc

Micelle BioPharma Inc

Mochida Pharmaceutical Co Ltd

Navipharm Co Ltd

NewAmsterdam Pharma BV

Nippon Chemiphar Co Ltd

Nissan Chemical Corp

NorthSea Therapeutics BV

NovalGen Ltd

Novartis AG

Nubiyota LLC

NuSirt Biopharma Inc

Omeros Corp

Orient Pharma Co Ltd

Pfizer Inc

Pharmena SA

Regeneron Pharmaceuticals Inc

Sequor Pharmaceuticals LLC

Shanghai Junshi Bioscience Co Ltd

Shenzhen Salubris Pharmaceuticals Co Ltd

Sirnaomics Inc

SJT Molecular Research SL

Staten Biotechnology BV

Suzhou Ribo Life Sciences Co Ltd

Sveikatal Inc

Synokem Pharmaceuticals Ltd

Tetranov International Inc

Torrent Pharmaceuticals Ltd

Viking Therapeutics Inc

Whan In Pharm Co Ltd

Yooyoung Pharm Co Ltd

Yungjin Pharm Co Ltd

Table of Contents

Table of Contents

Introduction

Dyslipidemia - Overview

Dyslipidemia - Therapeutics Development

Dyslipidemia - Therapeutics Assessment

Dyslipidemia - Companies Involved in Therapeutics Development

Dyslipidemia - Drug Profiles

Dyslipidemia - Dormant Projects

Dyslipidemia - Discontinued Products

Dyslipidemia - Product Development Milestones

Appendix

List of Tables

List of Tables

Number of Products under Development for Dyslipidemia, 2021

Number of Products under Development by Companies, 2021

Number of Products under Development by Universities/Institutes, 2021

Products under Development by Companies, 2021

Products under Development by Universities/Institutes, 2021

Number of Products by Stage and Target, 2021

Number of Products by Stage and Mechanism of Action, 2021

Number of Products by Stage and Route of Administration, 2021

Number of Products by Stage and Molecule Type, 2021

Dyslipidemia – Pipeline by 89bio Inc, 2021

Dyslipidemia – Pipeline by ABIONYX Pharma SA, 2021

Dyslipidemia – Pipeline by AD Pharmaceuticals Co Ltd, 2021

Dyslipidemia – Pipeline by Addpharma Inc, 2021

Dyslipidemia – Pipeline by Affina Biotechnologies Inc, 2021

Dyslipidemia – Pipeline by Afimmune Biopharma Ltd, 2021

Dyslipidemia – Pipeline by Akcea Therapeutics Inc, 2021

Dyslipidemia – Pipeline by Amarin Corp Plc, 2021

Dyslipidemia – Pipeline by Arrakis Therapeutics Inc, 2021

Dyslipidemia – Pipeline by Arrowhead Pharmaceuticals Inc, 2021

Dyslipidemia – Pipeline by AstraZeneca Plc, 2021

Dyslipidemia – Pipeline by AVVA Pharmaceuticals AG, 2021

Dyslipidemia – Pipeline by Bio-Thera Solutions Ltd, 2021

Dyslipidemia – Pipeline by BioRestorative Therapies Inc, 2021

Dyslipidemia – Pipeline by Boryung Pharmaceutical Co Ltd, 2021

Dyslipidemia – Pipeline by Cadila Healthcare Ltd, 2021

Dyslipidemia – Pipeline by Cardax Inc, 2021

Dyslipidemia – Pipeline by Celltrion Inc, 2021

Dyslipidemia – Pipeline by Celon Pharma SA, 2021

Dyslipidemia – Pipeline by Centaurus Therapeutics Inc, 2021

Dyslipidemia – Pipeline by Centeer BioTherapeutics Ltd Co, 2021

Dyslipidemia – Pipeline by Chong Kun Dang Holdings Corp, 2021

Dyslipidemia – Pipeline by CMG Pharmaceutical Co Ltd, 2021

Dyslipidemia – Pipeline by Corvidia Therapeutics Inc, 2021

Dyslipidemia – Pipeline by CVI Pharmaceuticals US Inc, 2021

Dyslipidemia – Pipeline by Daewon Pharmaceutical Co Ltd, 2021

Dyslipidemia – Pipeline by Daewoong Pharmaceutical Co Ltd, 2021

Dyslipidemia – Pipeline by Daiichi Sankyo Co Ltd, 2021

Dyslipidemia – Pipeline by Delivra Corp, 2021

Dyslipidemia – Dormant Projects, 2021

Dyslipidemia – Discontinued Products, 2021

List of Figures

List of Figures

Number of Products under Development for Dyslipidemia, 2021

Number of Products under Development by Companies, 2021

Number of Products under Development by Universities/Institutes, 2021

Number of Products by Top 10 Targets, 2021

Number of Products by Stage and Top 10 Targets, 2021

Number of Products by Top 10 Mechanism of Actions, 2021

Number of Products by Stage and Top 10 Mechanism of Actions, 2021

Number of Products by Routes of Administration, 2021

Number of Products by Stage and Routes of Administration, 2021

Number of Products by Top 10 Molecule Types, 2021

Number of Products by Stage and Top 10 Molecule Types, 2021

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports